In patient-derived neurons, tau mutations scupper lysosomes and SORLA shunts APP through different types of endosomes.
At Duke University, researchers discussed how injected stem cells might be tracked and used to treat neurodegenerative diseases.
Using a form of confocal microscopy and automated software, the method allows researchers to rapidly identify functional synapses within brain structures.
The drug slows functional decline in patients with mild disease and should be available to U.S. patients in August.
The ALS Ice Bucket Challenge has yielded more than $100 million—what research projects should get a share of the action?
Amyotrophic lateral sclerosis, already a rare condition affecting one to three people in 100,000, nonetheless garners most of the attention in the field of motor neuron disease...
People who lived in impoverished neighborhoods in their last year of life had greater odds of having died with AD neuropathology.
Islet amyloid protein and Aβ fibrils share similar folds.
Prompted by striking brain pathology in both contact sport athletes and military veterans, scientists are now defining a new disease...
Researchers used PET scans from 4,000 people to link RBFOX1 risk variants to amyloidosis. People with lower RBFOX1 expression in their brains had more amyloid and worse cognition.
Autopsy data confirm that current tau PET tracers are unsuitable for some primary tauopathies. CryoEM structures help researchers find new ligands for tau and α-synuclein.
At the HAI 2020 conference, the tracers PI-2620 and APN-1607 appeared to bind frontotemporal dementia tau. MK-6240 looked highly sensitive. And JNJ-067 and SNFT-1 are two new kids in town.
CryoEM helps explain how the inhibitory receptors open and close their ion channels.
New drug application is first for Alzheimer’s disease in the U.S. since 2003, and first based on amyloid hypothesis.
The findings hint at a liver-brain axis that transmits inflammation from periphery to brain, and could suggest therapeutic targets for preserving brain function.